RANCHO CORDOVA, Calif., Jan. 4, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and autologous
As a result, ThermoGenesis is now a wholly owned subsidiary of Cesca with a focus on the development and commercialization of automated medical devices and technologies for cell-based therapies, including stem cell banking, point-of-care applications, and large-scale cell manufacturing of immunotherapy drugs, such as chimeric antigen receptor (CAR) T cells. Specifically, ThermoGenesis' proprietary technology platforms include:
In connection with the reorganization, Ms. Haihong Zhu, president of ThermoGenesis, has also been appointed president of its newly formed subsidiary, CARTXpress Bio, Inc. Additionally, beginning with the filing of company's first quarter 2019 financial results, Cesca will report ThermoGenesis as a 100% owned device division, according to business segment accounting requirements.
Chris Xu, Ph.D., Cesca's chief executive officer, commented, "Under this revised corporate structure, we believe that we can more effectively unlock the true underlying value of each area of focus with dedicated leadership teams and solid strategies for growth."
About ThermoGenesis Corp. ThermoGenesis Corp. is a wholly owned subsidiary of Cesca Therapeutics with a focus on the development and commercialization of automated medical devices and technologies for cell-based therapies, including stem cell banking, point-of-care applications, and large-scale cell manufacturing. For more information, visit: www.thermogenesis.com.
About Cesca Therapeutics Inc. Cesca Therapeutics Inc. is a market leader in automated cellular processing technologies and autologous cell therapies for regenerative medicine. For more information, visit: www.cescatherapeutics.com.
Company Contact: Cesca Therapeutics Inc. Wendy Samford916email@example.com
Investor Contact: Rx CommunicationsPaula Schwartz917firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/cesca-therapeutics-acquires-remaining-ownership-stake-in-thermogenesis-and-forms-new-thermogenesis-subsidiary-cartxpress-bio-inc-to-focus-on-its-car-txpress-cellular-processing-platform-300772840.html
SOURCE Cesca Therapeutics Inc.
Subscribe to our Free Newsletters!